Roche successfully concludes talks with p-CPA for Vabysmo® (faricimab)

May 29, 2023

Roche has announced that it has successfully concluded meetings with pan-Canadian Pharmaceutical Alliance (pCPA) regarding Vabysmo® (faricimab).  The company said that it secured a letter of intent with the pCPA for Vabysmo®, a treatment indicated for neovascular age-related macular degeneration and diabetic macular edema.  The pCPA’s mandate is to enhance patient access to clinically relevant and cost-effective drug treatment options by conducting collective, expert-informed negotiations for drugs. 

Roche Canada intends to work with other provincial jurisdictions to make Vabysmo® available as soon as possible through public drug plans. 

This news comes a few weeks after the FDA accepted Roche’s sBLA for Vabysmo® to treat macular edema following retinal vein occlusion.  

Print Page Mail Article